On September 2, Beximco Pharmaceuticals, a branch of Beximco Group won the Superbrands of Bangladesh award for 2018-2020. The event was held at the Radisson Blu Dhaka Water Garden hotel. Other leading brands from multiple industries won in other categories.
Since its inception in 1993, Superbrands has marked its presence in 88 countries as a global business of publications and media communication. The winners were chosen after the decision of a council comprising of 12 renowned brand experts. As per a statement from organizer Superbrands Bangladesh, this is the biggest symbol of success for brands.
Salman F Rahman’s Beximco Pharmaceuticals can now have a ‘Superbrands Award Seal’ on their products and advertisement materials. Going by the claims of an independent research, almost 70 per cent of the buyers tend to purchase products, which have the aforementioned seal. The company had also won the award back in the 2010 edition of Superbrands of Bangladesh.
“As Bangladesh steps into the next phase of progress and development, being part of global Superbrands, and recognizing Bangladesh’s Superbrands will play a key role in our economic journey,” added Shariful Islam, coordinator of Superbrands Bangladesh while speaking at the award ceremony in Dhaka.
Reiterating the FDA approval of Nadolol tablets bagged by Salman F Rahman’s Beximco Pharmaceuticals in August, the company is the flag bearer of Bangladesh in the global scenario of medicines. Beximco’s Managing Director Nazmul Hassan had expressed, “Beximco Pharma remains the only Bangladeshi company to export pharmaceutical products to the US, which is a validation of our expertise in offering specialized generic products in a global setting.”
Beximco Pharmaceuticals is well-known in the global markets as one of the leading suppliers of medicines from Bangladesh. This comes after the recognition of their top-notch facilities by experts from USA, Canada, Europe, etc., along with consistent production efforts of more than 300 generic medicines.
With five product approvals in the United States by a Bangladeshi company along with a portfolio of more than 500 products in the overall global market, the country’s increasing influence in affordable medicines sector is impossible to overlook.
